JRCT ID: jRCT1051230180
Registered date:14/02/2024
A study of treatment of multi-organ dysfunction with MSC-CM
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Multi-Organ Dysfunction |
Date of first enrollment | 07/02/2024 |
Target sample size | 5 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | Performing necessary tests based on the patient's condition. For example: Blood tests: Hematology tests: Measurement of red blood cells, white blood cells, and platelet count. Biochemical tests: Evaluation of liver function, kidney function, and electrolytes. Coagulation tests: Assessment of coagulation factors and prothrombin time. Measurement of inflammatory markers: C-reactive protein (CRP): Assessment of the degree of inflammation. Blood smear (white blood cell differential): Evaluation of white blood cell count and types. Blood gas analysis: Arterial blood gas analysis: Evaluation of acid-base balance, oxygen, and carbon dioxide. Imaging tests: X-ray: Evaluation of organ abnormalities, such as chest X-rays. CT (Computed Tomography): Detailed assessment of internal organ abnormalities and injuries. Electrocardiogram (ECG): Evaluation of heart rhythm and function. Ultrasonography: Evaluation of organs such as the heart and abdominal organs. Urine analysis: Evaluation of kidney function and urinary tract abnormalities. Tumor marker tests: Assessment of the presence and progression of cancer. Renal function tests: Measurement of creatinine and blood urea nitrogen: Evaluation of kidney function. |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | 1 Individuals who did not experience satisfactory treatment effects for multi-organ dysfunction with standard therapy. 2 Individuals who, due to concerns about side effects or other reasons, do not wish to undergo treatment with drugs commonly used in standard therapy, and whose physicians have deemed treatment with culture supernatant appropriate for multi-organ dysfunction. The patient selection criteria are outlined below. Inclusion Criteria Patients meeting the following criteria will be included: 1 Individuals aged 18 years or older. 2 Individuals possessing normal capacity to consent. 3 Individuals who have been provided with an informed consent document regarding this treatment, received sufficient explanation, and provided written consent voluntarily. 4 Individuals for whom the attending physician has recognized the necessity of treatment. |
Exclude criteria | <Exclusion Criteria> Individuals meeting any of the following conditions will be excluded from the study: 1. Users of narcotics or stimulants. 2. Individuals deemed inappropriate by the attending physician. |
Related Information
Primary Sponsor | Sugawara Kou |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Kou Sugawara |
Address | 9-18 Doyacho, Ichinosek.Iwate Iwate Japan 021-0023 |
Telephone | +81-191-23-0501 |
sugawaraseikei918@outlook.jp | |
Affiliation | Sugawara Orthopedic Clinic |
Scientific contact | |
Name | Kou Sugawara |
Address | 9-18 Doyacho, Ichinoseki, Iwate Iwate Japan 021-0023 |
Telephone | +81-191-23-0501 |
sugawaraseikei918@outlook.jp | |
Affiliation | Sugawara Orthopedic Clinic |